-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GoVL5EsH5LQ2R/CNKRjfm1xeAil91MTdPa48u1fnxSCgyFEIywC6eFALzlR76tDD 9o7U9qlTFapc5X5mBIbvwA== 0001021408-03-006734.txt : 20030429 0001021408-03-006734.hdr.sgml : 20030429 20030429162741 ACCESSION NUMBER: 0001021408-03-006734 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030429 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOSE TECHNOLOGIES INC CENTRAL INDEX KEY: 0000877902 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133549286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27718 FILM NUMBER: 03669857 BUSINESS ADDRESS: STREET 1: 102 WITMER RD CITY: HORSHAM STATE: PA ZIP: 19044 BUSINESS PHONE: 2154415890 MAIL ADDRESS: STREET 1: 102 WITMER ROAD CITY: HORSHAM STATE: PA ZIP: 19044 FORMER COMPANY: FORMER CONFORMED NAME: NEOSE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950817 8-K 1 d8k.htm FORM 8-K--NEOSE TECHNOLOGIES, INC. Form 8-K--Neose Technologies, Inc.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 

Current Report Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 29, 2003

 


 

NEOSE TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-27718

 

13-3549286

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

102 Witmer Road, Horsham, Pennsylvania

 

19044

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (215) 315-9000

 



 

Item 5. Other Events.

 

Announcement of License. On April 29, 2003, Neose Technologies, Inc. (the “Company”) announced that it has signed a license agreement with GlaxoSmithKline.

 

Item 7. Financial Statements, Pro Forma Financial Information And Exhibits.

 

(a) Financial Statements of Businesses Acquired: None

 

(b) Pro Forma Financial Information: None

 

(c) Exhibits: Reference is made to the Exhibit Index annexed hereto and made a part hereof.

 

-2-


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

NEOSE TECHNOLOGIES, INC.

By:

 

/s/    C. BOYD CLARKE


   

C. Boyd Clarke

President and Chief Executive Officer

 

Dated: April 29, 2003

 


 

EXHIBIT INDEX

 

Exhibit No.


  

Description


99.1

  

Press release issued on April 29, 2003 by Neose Technologies, Inc.

 

-2-

EX-99.1 3 dex991.htm PRESS RELEASE Press Release

 

Exhibit 99.1

NEOSE TECHNOLOGIES, INC.

 

102 Witmer Road, Horsham, PA 19044     215.315.9000     fax:215.315.9100

 

email: info@neose.com     www.neose.com

 

Neose Technologies Signs License Agreement with GSK

 

Horsham, PA, April 29, 2003. Neose Technologies, Inc. (Nasdaq NM: NTEC) announced today that it has entered into an agreement with GlaxoSmithKline (FTSE: GSK and NYSE: GSK), to license certain intellectual property rights of Neose. Under the agreement, GSK has an exclusive license to develop, make and sell certain human vaccines for the prevention, control or treatment of diseases. GSK also has a non-exclusive right to use any other patents owned by Neose that are required to practice its exclusively licensed rights in the same field.

 

Under the agreement, Neose will receive undisclosed license fees, milestone payments, and royalties on product sales.

 

Neose is a biopharmaceutical company focused on the improvement of protein therapeutics through the application of its proprietary technologies. By leveraging its GlycoAdvance and GlycoPEGylation technologies, Neose is developing proprietary protein drugs that are improved versions of currently marketed therapeutics with proven efficacy. These next generation proteins are expected to offer significant advantages, such as less frequent dosing and improved safety and efficacy. In addition to developing its own products or co-developing products with others, Neose is entering into strategic partnerships for the inclusion of its technologies into products being developed by other biotech and pharmaceutical companies.

 

CONTACTS:

 

Neose Technologies, Inc.

Robert I. Kriebel

Sr. Vice President and Chief Financial Officer

Barbara Krauter

Manager, Investor Relations

(215) 315-9000

 

For more information, please visit www.neose.com.

 

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of Part II of our Annual Report on Form 10-K for the year ended December 31, 2002 entitled “Factors Affecting the Company’s Prospects.”

 

-----END PRIVACY-ENHANCED MESSAGE-----